Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...

Linda Yaccarino has a new job in a vastly different industry weeks after her exit as CEO of X, Elon Musk 's social discourse ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Inspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions ...

MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.

Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...